Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF10073 in Idiopathic Pulmonary Fibrosis (IPF)
NCT07876284Phase 1Not yet recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2026
- Primary completion
- Aug 2027
01
Overview
Phase 1, randomised, double-blind trial of CHF10073 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Treatment-Emergent Adverse Events, Systolic and Diastolic Blood Pressure at Day 28 and 11 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
CHF10073
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07876284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876284.